Newton: Transports ...
Health Care: Drugs
Gilead Sciences Inc (GILD: NASDAQ)
$54.30 -0.78 | -1.41%
02/08/12 - 02:45 PM ET
8.29M / 9.45M
Vol / Avg. Vol:54.56 / 55.08
Open / Prev. Close:53.83 - 54.90
Today's Range:34.45 - 56.50
52 Wk Range:34.56%
Performance YTD:TheStreet Rating:
Portfolios with GILD
- Portfolio NameUser Type
- Contributor10 Health Care Stocks to Watch
- ContributorStocks At New 52-Week Highs...
- UserDec 2011
- ProDaniel Loeb - Third Point
- UserBerliner
- Contributor5 Biotech Stocks for 2012
- ProAdage Capital
- Contributor5 Stocks for Bargain Hunters
- ProMoore Capital
- Contributor10 Hep C Stocks on Wall Str...
Latest GILD Headlines from TheStreet
- Analysts' Actions: FDX, BWLD, GILD, MGM 02.06.12 | 09:02 am
- Gilead Reaches New 52-Week High (GILD) 02.03.12 | 01:02 pm
- Idenix Falls Casualty to Gilead Hep C Hoopla 02.03.12 | 11:02 am
- Gilead Wows With New Hep C Data, Boxing Out Poor 2012 Guidance 02.03.12 | 07:02 am
- Gilead Sciences' CEO Discusses Q4 2011 Results - Earnings Call Transcript 02.03.12 | 12:02 am
- Vertex Hep C Sales Growth Nears End 01.31.12 | 06:01 am
- 10 Health Care Stocks to Watch 01.27.12 | 05:01 pm
- 6 Stocks at New 52-Week Highs 01.27.12 | 02:01 pm
- Biotech Stock Mailbag: Vical, Hep C Drugs 01.27.12 | 07:01 am
- Gilead Stock Hits New 52-Week High (GILD) 01.26.12 | 12:01 pm
Press Releases for GILD
- Gilead Sciences Announces Fourth Quarter And Full Year 2011 Financial Results - Business Wire 02.02.12 | 04:02 pm
- Gilead Sciences To Release Fourth Quarter And Year End 2011 Financial Results On Thursday, February 2, 2012 - Business Wire 01.26.12 | 04:01 pm
- Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug Of Tenofovir For The Treatment Of HIV - Business Wire 01.24.12 | 04:01 pm
- U.S. Food And Drug Administration Approves New Formulations Of Viread® For Use By Children Living With HIV - Business Wire 01.18.12 | 07:01 pm
- Roy D. Baynes, MD, PhD, To Join Gilead Sciences As Senior Vice President, Oncology Therapeutics - Business Wire 01.18.12 | 04:01 pm
- Gilead Sciences Completes Acquisition Of Pharmasset, Inc. - Business Wire 01.17.12 | 05:01 pm
- Gilead Sciences Completes Tender Offer For All Outstanding Shares Of Pharmasset, Inc. - Business Wire 01.12.12 | 01:01 am
- Gilead Sciences Announces Early Termination Of Hart-Scott-Rodino Waiting Period - Business Wire 01.06.12 | 04:01 pm
- Gilead Sciences To Present At The 30th Annual JPMorgan Healthcare Conference On Monday, January 9 - Business Wire 01.05.12 | 05:01 pm
- U.S. FDA Accepts New Drug Application For Gilead’s Once-Daily, Single-Tablet Quad HIV Regimen - Business Wire 12.23.11 | 05:12 pm
Partner Headlines for GILD
- Company News for February 6, 2012 - Corporate Summary - Zacks 02.06.12 | 10:02 am
- Gilead Sciences Soars On "Striking" Clinical Trial Data - Benzinga 02.03.12 | 01:02 pm
- Gilead Misses EPS Ests, Sales Up - Analyst Blog - Zacks 02.03.12 | 10:02 am
- UPDATE: JP Morgan Raises Target to $65 on Gilead Sciences - Benzinga 02.03.12 | 09:02 am
- 7 Stocks In Overbought Territory - Seeking Alpha 01.29.12 | 07:01 am
- Big Biotech Fuels M&A Activity - Seeking Alpha 01.29.12 | 07:01 am
- Biotech Equities Continue To Benefit From Discoveries And Acquisitions In 2012 - Seeking Alpha 01.27.12 | 09:01 am
- The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Inhibitex, Vertex Pharmaceuticals and Merck - Press Releases - Zacks 01.20.12 | 09:01 am
- Biotech Stocks On A Tear: I Like Celgene - Seeking Alpha 01.13.12 | 09:01 am
- Analyzing 5 Biotech Stocks And Their Takeover Potential - Seeking Alpha 01.13.12 | 08:01 am
